Literature DB >> 21190059

Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.

Fulin Wang1, Guangyu Qiao, Xin Lou.   

Abstract

Primary spinal cord oligodendroglial tumor is very rare, and in only one patient with spinal cord oligodendroglioma has a deletion of chromosome 1p/19q been reported. We present the case of an 18-year-old girl, who had one-year lower back pain and one-month lower limb weakness. Magnetic resonance images of the spinal cord showed an intramedullary mass from level T8 to T10, which was then radically removed. Histology revealed an anaplastic oligodendroglioma. The patient was treated with radiotherapy postoperatively. Eight months after the treatment, follow-up magnetic resonance images disclosed an enhancing intramedullary mass at level T4-T8; recurrence of the tumor was therefore diagnosed. Maximum surgical removal of the recurrent tumor was performed, diagnosis of anaplastic oligodendroglioma was made, and a chromosome 1p deletion was determined by FISH. After treatment with temozolomide for six months, the patient had a remarkable improvement of her lower limb symptoms, and complete imaging regression of the residual tumor showed no evidence of recurrence at any other sites. The most recent MRI of brain and spinal cord showed postoperative changes without evidence of tumor recurrence of the spine and oligodendrogliomatosis along the cerebral-spinal axis. To our knowledge, this is the first report of a recurrent anaplastic oligodendroglioma with 1p deletion occurring in the spinal cord. It is also the first case of the patient with recurrent intramedullary anaplastic oligodendroglioma who had a significant clinical improvement and complete imaging remission after subtotal resection then treatment with temozolomide chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190059     DOI: 10.1007/s11060-010-0493-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Tumors of the spinal cord associated with choking of the optic disks.

Authors:  J G LOVE; H P WAGENER; H W WOLTMAN
Journal:  AMA Arch Neurol Psychiatry       Date:  1951-08

2.  Temozolomide chemotherapy in recurrent oligodendroglioma.

Authors:  M J van den Bent; F Keime-Guibert; A A Brandes; M J Taphoorn; J M Kros; F A Eskens; A F Carpentier
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

Review 3.  Primary spinal cord oligodendroglioma. Case illustration.

Authors:  D Gürkanlar; H Koçak; A Aciduman; E Yucel; O Ekinci
Journal:  Neurocirugia (Astur)       Date:  2006-12       Impact factor: 0.553

4.  Intramedullary "holocord" oligodendroglioma: case report.

Authors:  C A Pagni; S Canavero; E Gaidolfi
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

5.  Primary spinal cord oligodendroglioma: case report and review of the literature.

Authors:  Kostas N Fountas; Ioannis Karampelas; Leonidas G Nikolakakos; E Christopher Troup; Joe Sam Robinson
Journal:  Childs Nerv Syst       Date:  2004-05-12       Impact factor: 1.475

6.  Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.

Authors:  Netta Levin; Iris Lavon; Bracha Zelikovitsh; Dana Fuchs; Felix Bokstein; Yakov Fellig; Tali Siegal
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

7.  Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas.

Authors:  Kavita S Reddy
Journal:  Cancer Genet Cytogenet       Date:  2008-07-15

8.  Primary spinal cord tumors treated with surgery and postoperative irradiation.

Authors:  D M Garcia
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-11       Impact factor: 7.038

Review 9.  Metastatic anaplastic oligodendroglioma.

Authors:  D R Macdonald; R A O'Brien; J J Gilbert; J G Cairncross
Journal:  Neurology       Date:  1989-12       Impact factor: 9.910

10.  Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis.

Authors:  Kern H Guppy; Paul T Akins; Gregory S Moes; Michael D Prados
Journal:  J Neurosurg Spine       Date:  2009-06
View more
  5 in total

1.  Primary Spinal Cord Oligodendroglioma with Postoperative Adjuvant Radiotherapy: A Case Report.

Authors:  Woon Tak Yuh; Chun Kee Chung; Sung-Hye Park
Journal:  Korean J Spine       Date:  2015-09-30

2.  Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma.

Authors:  Amy K Bruzek; Andrew H Zureick; Paul E McKeever; Hugh J L Garton; Patricia L Robertson; Rajen Mody; Carl J Koschmann
Journal:  Pediatr Blood Cancer       Date:  2016-11-10       Impact factor: 3.167

3.  Temozolomide or bevacizumab for spinal cord high-grade gliomas.

Authors:  Thomas J Kaley; Ijah Mondesire-Crump; Igor T Gavrilovic
Journal:  J Neurooncol       Date:  2012-06-08       Impact factor: 4.130

4.  A very rare spinal cord tumor primary spinal oligodendroglioma: A review of sixty cases in the literature.

Authors:  Askin Esen Hasturk; Emre Cemal Gokce; Cagri Elbir; Gulce Gel; Suat Canbay
Journal:  J Craniovertebr Junction Spine       Date:  2017 Jul-Sep

Review 5.  Holocord oligodendroglioma with intracranial extension in a young adult: a case report and review of literature.

Authors:  Romulus Emmanuel H Cruz; Ranhel C De Roxas; Carmela Concepcion A Sales-Callangan; Roland Dominic G Jamora
Journal:  CNS Oncol       Date:  2018-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.